GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
FiercePharma2d
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Baird starts Catalyst Pharma with Outperform, $28 target
Baird initiated coverage on Catalyst Pharmaceutical Partners (NASDAQ:CPRX) with an Outperform rating and set a price target ...
Money Morning9d
3 Pharma Stocks Getting Fat Off GLP-1: Here's the Best Buy Now
Novo Nordisk subsequently developed Wegovy to specifically target weight-loss ... more than tripled in value as Mounjaro sales took off, the pharmaceutical distributors are the better GLP-1 ...